Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
作者： J. Van Der Palen , M. G. V. M. Russel , S. Corporaal , W. M. Smit , W. M. Smit
DOI:
关键词:
摘要: A B s T r C Background: inoperable or metastatic oesophagogastric adenocarcinoma has a poor prognosis. f rom the many different chemotherapeutic regimens used in past, combination of epirubicin, cisplatin and continuous 5-fluorouracil infusion (EC ) showed consistent response rate ± 50% with acceptable toxicity. Continuous 5fu may be replaced by oral fluoropyrimidines. h ere we evaluate treatment epirubicin combined capecitabine (ECC), replacing intravenous 5- fu infusion. Methods: etrospectively, analysed 23 consecutive patients who were treated for during 2002 2003. esults: The overall was 57%; another 26% achieved stable disease only 17% had progressive disease. median duration 6.4 months; survival 9.0 months. Previously (n=10) significantly worse (20%) compared previously untreated (85%). nonsignificant difference found between these groups (3.9 vs 9.8 months patients). An incidence grade 3 4 toxicity found. Conclusion: Capecitabine is an effective safe alternative to EC ,
参考文章(24)
D. Cunningham, W. H. Allum, S. P. Stenning, S. Weeden, Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971) Journal of Clinical Oncology. ,vol. 23, pp. 4001- 4001 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.4001
A Webb, D Cunningham, J H Scarffe, P Harper, A Norman, J K Joffe, M Hughes, J Mansi, M Findlay, A Hill, J Oates, M Nicolson, T Hickish, M O'Brien, T Iveson, M Watson, C Underhill, A Wardley, M Meehan, Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology. ,vol. 15, pp. 261- 267 ,(1997) , 10.1200/JCO.1997.15.1.261
Udo Vanhoefer, Philippe Rougier, Hansjochen Wilke, Michel P. Ducreux, Angel J. Lacave, Eric Van Cutsem, Manfred Planker, José Guimaraes Dos Santos, Pascal Piedbois, Bernard Paillot, Heinrich Bodenstein, Hans-Jochen Schmoll, Harry Bleiberg, Bernard Nordlinger, Marie-Laure Couvreur, Benoit Baron, Jacques A. Wils, Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group Journal of Clinical Oncology. ,vol. 18, pp. 2648- 2657 ,(2000) , 10.1200/JCO.2000.18.14.2648
J J Lokich, J D Ahlgren, J J Gullo, J A Philips, J G Fryer, A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. Journal of Clinical Oncology. ,vol. 7, pp. 425- 432 ,(1989) , 10.1200/JCO.1989.7.4.425
G Liu, E Franssen, M I Fitch, E Warner, Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology. ,vol. 15, pp. 110- 115 ,(1997) , 10.1200/JCO.1997.15.1.110
D Kelsen, O T Atiq, L Saltz, D Niedzwiecki, D Ginn, D Chapman, R Heelan, C Lightdale, V Vinciguerra, M Brennan, FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. Journal of Clinical Oncology. ,vol. 10, pp. 541- 548 ,(1992) , 10.1200/JCO.1992.10.4.541
J A Wils, H O Klein, D J Wagener, H Bleiberg, H Reis, F Korsten, T Conroy, M Fickers, S Leyvraz, M Buyse, Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer: a trial of the European organization for research and treatment of cancer gastrointestinal tract cooperative group Journal of Clinical Oncology. ,vol. 9, pp. 827- 831 ,(1991) , 10.1200/JCO.1991.9.5.827
Aris Bamias, Mark E. Hill, David Cunningham, Andrew R. Norman, Fareeda Y. Ahmed, Andrew Webb, Maggie Watson, Andrea S. Hill, Marianne C. Nicolson, Mary E. O'Brien, T. Christopher Evans, Viola Nicolson, Epirubicin, Cisplatin, and Protracted Venous Infusion of 5-Fluorouracil for Esophagogastric Adenocarcinoma Response, Toxicity, Quality of Life, and Survival Cancer. ,vol. 77, pp. 1978- 1985 ,(1996) , 10.1002/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D
J S Waters, A Norman, D Cunningham, J H Scarffe, A Webb, P Harper, J K Joffe, M Mackean, J Mansi, M Leahy, A Hill, J Oates, S Rao, M Nicolson, T Hickish, Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer. ,vol. 80, pp. 269- 272 ,(1999) , 10.1038/SJ.BJC.6690350
MC Etienne, S Bernard, JL Fischel, P Formento, J Gioanni, J Santini, F Demard, M Schneider, G Milano, Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. British Journal of Cancer. ,vol. 63, pp. 372- 377 ,(1991) , 10.1038/BJC.1991.88